Thalidomide scandal

Thalidomide Scandal refers to one of the darkest episodes in pharmaceutical history, where the drug thalidomide, used by pregnant women to control symptoms of morning sickness in the late 1950s and early 1960s, led to thousands of babies being born with severe deformities. This incident led to significant changes in drug regulation and testing protocols worldwide.

Background

Thalidomide was first marketed in 1957 by the German pharmaceutical company Grünenthal, and was widely used in 46 countries. It was promoted as a wonder drug for insomnia, coughs, colds, and headaches. Crucially, it was also prescribed to pregnant women to relieve morning sickness. However, the drug had not been sufficiently tested for its effects on fetal development.

Consequences

The use of thalidomide during early pregnancy resulted in the birth of children with severe physical malformations, a condition known as phocomelia, in which the limbs are extremely underdeveloped or absent. Other deformities included damage to the ears, heart, kidneys, and digestive tract. More than 10,000 children were affected worldwide, and thousands of miscarriages were also attributed to thalidomide. Many of the affected children did not survive infancy, and those who did faced significant challenges and discrimination.

Discovery of the Link

The link between thalidomide and birth defects was first suggested by Dr. Widukind Lenz in Germany and independently by Dr. William McBride in Australia in the early 1960s. Once the connection was made, the drug was quickly withdrawn from the market. However, by this time, the damage had been done to thousands of families worldwide.

Legal Implications and Compensation

The aftermath of the thalidomide scandal led to numerous lawsuits. In 1970, a significant legal settlement was reached in the UK, providing compensation to victims. Similar settlements were reached in other countries. However, many of the victims and their families have argued that the compensation has not been sufficient to cover the lifelong medical costs and support needs.

Impact on Drug Regulation

The thalidomide scandal led to profound changes in drug regulation and testing. In the United States, the Food and Drug Administration (FDA) had already refused to approve thalidomide before the scandal broke, due to concerns about its safety. The incident validated their caution and led to a strengthening of the FDA's powers and a global tightening of drug approval processes. The Kefauver Harris Amendment or "Drug Efficacy Amendment" was passed in 1962, requiring drug manufacturers to provide proof of the effectiveness and safety of their drugs before approval.

Thalidomide Today

Despite its infamous history, thalidomide is still used today, albeit under very strict controls, for the treatment of a handful of serious medical conditions, including multiple myeloma and certain skin conditions associated with leprosy.

Legacy

The legacy of the thalidomide scandal continues to shape modern medical and pharmaceutical practices. It underscored the essential need for rigorous drug testing and regulatory oversight, especially for drugs intended for use in pregnant women. It also highlighted the importance of pharmacovigilance—the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems.

Thalidomide's victims and their families formed advocacy groups to fight for compensation and to ensure that the lessons from the scandal were not forgotten. One such organization is the Thalidomide Society in the UK, which provides support to individuals and families affected by thalidomide.

Modern Use of Thalidomide

Despite its dark past, thalidomide is still used today under strict regulations for the treatment of certain medical conditions. The drug has shown effectiveness in treating complications of leprosy and multiple myeloma, a type of blood cancer. Patients who are prescribed thalidomide today must adhere to strict precautions to avoid pregnancy due to the drug's teratogenic effects.

External Links

• The Thalidomide Society

See Also

• Drug safety
• Pharmaceutical industry
• History of medicine

References

• Bren L. (2001). "Frances Oldham Kelsey: FDA Medical Reviewer Leaves Her Mark on History". FDA Consumer. 35 (2): 24–9. PMID 11458545.
• McBride WG (1961). "Thalidomide and congenital abnormalities". Lancet. 278 (7216): 1358. doi
• Stephens TD, Fillmore BJ, Norris BJ (2000). "Blastomere culture and analysis". Methods in Molecular Biology. 135: 279–293.
• Lenz W (1988). "A short history of thalidomide embryopathy". Teratology. 38 (3): 203–215. doi:10.1002/tera.1420380303. PMID 3069578.
• Vargesson N (2015). "Thalidomide-induced teratogenesis: history and mechanisms". Birth Defects Research Part C: Embryo Today: Reviews. 105 (2): 140–156. doi:10.1002/bdrc.21096. PMID 26043938.

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia

• 
  Thalidomide effects
• 
  Thalidomide scandal
• 
  Grünenthal logo
• 
  Artificial limbs for a thalidomide child
• 
  Frances Oldham Kelsey and John F. Kennedy
• 
  Thalidomide Memorial in Cardiff
• 
  Niko von Glasow